For most hemodynamically stable patients,<unk> therapy is NOT indicated
Major controversy exists regarding<unk> therapy in submassive PE.  The mortality benefit may be greatest in patients with right ventricular dysfunction. 
Bleeding risk is increased with increasing age especially in the group ≥ 65 yo
There is no evidence suggesting administering<unk>  within a certain window of time improves outcomes 
There is no evidence suggesting administering<unk>  empirically during cardiac arrest improves outcomes
In patients with PEA secondary to confirmed PE, administration of<unk>  may be indicated
In patients with PEA secondary to confirmed PE, administration of<unk>  may be indicated
Thrombolytics for pulmonary embolism
Thrombolytics for STEMI
Thrombolytics for acute ischemic stroke
Balloon tamponade for massive GI bleeding
Resuscitative endovascular balloon occlusion of the aorta
Anti-platelet agent reversal
Cardiovascular antibiotics
Formal echocardiography